SEC Form 4 · accession 0001209191-19-015043
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William F Doyle
Officer — Executive Chairman · Director
Period of report
Feb 27, 2019
Accepted (ET)
Mar 1, 2019 · 4:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Feb 27, 2019 | M | 9,260 | $52.90 | A | 921,403 | D | |
| Ordinary SharesF1 | Feb 28, 2019 | S | 3,097 | $53.68 | D | 918,306 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF2 | $0.00 | Feb 27, 2019 | M | 9,260 | D | Feb 27, 2019 | — | Ordinary Shares | 9,260 | 18,518 | D |
Explanation of responses
- F1Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the Issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- F2Fully vested as of the date hereof.